Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
71P - When neighbors play a role: The importance of interacting proteins in the tumorigenic effect of cancer driver genes
Presenter: Margarida Carrolo
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - SNCG promotes the malignant progression of hepatocellular carcinoma by activation EGFR signaling and recycling
Presenter: Yue Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma
Presenter: Sarah Orlando
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - The influence of genetic phenotype on prognosis of osteosarcoma
Presenter: Nasirov Kamalovich
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Immune engager compounds screening using CRC patient-derived organoids
Presenter: Claudia Maria A. Pinna
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Presenter: Juan Jiménez-Vacas
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Exploring ecDNA heterogeneity and evolution in non-small cell lung cancer
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Targeting galectin-9 in BRCA mutant breast cancer
Presenter: Chun Yan So
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Suppression of glioblastoma progression by FDA-approved central nervous system-accumulating drugs via autophagy modulation and ER stress-induced apoptosis
Presenter: Smita Dey
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Evaluating the effect of lenvatinib-resistance in hepatocellular carcinoma cells and in lenvatinib-resistant patient-derived PBMCs
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract